A

Amgen Inc. (AMGN)

NMS – Real vaqt narxi. Valyuta: USD

336.29

+6.70 (2.03%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

A

Amgen Inc. (AMGN)

NMS – Real vaqt narxi. Valyuta: USD

336.29

+6.70 (2.03%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

New Study Finds These Sectors Produce the Most 100-Bagger Stocks

On a recent episode of The Compound and Friends, hosts Josh Brown and Michael Batnick sat down with former Janus analyst Matt Ancrum to discuss his study of 100-bagger stocks.

08.05.2026

2 Dividend Stocks to Double Up On Right Now

Amgen is handling a recent patent cliff pretty well. Merck is well prepared for its own upcoming patent cliff.

07.05.2026

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif., May 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m.

06.05.2026

RPRX vs. AMGN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Amgen (AMGN). But which of these two stocks presents investors with the better value opportunity right now?

04.05.2026

Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN | AMGN Price Prediction) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating.

04.05.2026

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

04.05.2026

Amgen to invest additional $300 million to boost US manufacturing footprint

Amgen said on Monday it was investing an additional $300 million in Puerto Rico to expand its U.S. ‌manufacturing network.

Videolar

14.01.2026

Neutral

Amgen CEO Bob Bradway goes one-on-one with Jim Cramer

14.01.2026

Positive

Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss

Press-relizlar

04.05.2026

AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR

Investment Strengthens American Manufacturing, Supply Chain Resilience and Next-Generation Technology THOUSAND OAKS, Calif., May 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to invest an additional $300 million in its U.S. manufacturing network to further advance U.S.-based production capacity, enhance next-generation technologies and support a reliable supply of medicines for patients.

19.12.2025

Neutral

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

13.11.2025

Positive

Trade Tracker: Bill Baruch buys more Amgen

22.04.2026

AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER

Organizational Changes Further Emphasize Integration of Biology and Technology THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of David M.

06.04.2026

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE

Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction in Proptosis; Greater Than 3 mm THOUSAND OAKS, Calif., April 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease (TED).

01.04.2026

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ: AMGN) to evaluate Zai Lab's investigational delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci, formerly ZL-1310), in combination with Amgen's IMDELLTRA® (tarlatamab-dlle), a DLL3-targeting Bispecific T-cell Engager (BiTE®) therapy in patients with extensive-stage small cell lung canc.

Search stocks

Amgen Inc. (AMGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Amgen Inc. (AMGN)

New Study Finds These Sectors Produce the Most 100-Bagger Stocks

2 Dividend Stocks to Double Up On Right Now

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

RPRX vs. AMGN: Which Stock Is the Better Value Option?

Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Amgen to invest additional $300 million to boost US manufacturing footprint

Videolar

Press-relizlar

AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR

AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy